Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emcure PharmaceuticalsNSE:EMCURE +0.85%41 Return-on-Tangible-Asset is 13.82% as of Jun. 2026, which is 50% above its 10-year median of 9.23. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Emcure Pharmaceuticals ranks better than 82.13% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Emcure Pharmaceuticals's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹11,759 Mil. Emcure Pharmaceuticals's average total tangible assets for the quarter that ended in Jun. 2026 was ₹85,114 Mil. Therefore, Emcure Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 13.82%.
The historical rank and industry rank for Emcure Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
NSE:EMCURE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.51 Med: 9.23 Max: 12.55
Current: 12.55
During the past 6 years, Emcure Pharmaceuticals's highest Return-on-Tangible-Asset was 12.55%. The lowest was 6.51%. And the median was 9.23%.
NSE:EMCURE's Return-on-Tangible-Asset is ranked better than 82.13% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.99
vs NSE:EMCURE: 12.55
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Emcure Pharmaceuticals Return-on-Tangible-Asset Related Terms
Emcure Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Emcure Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:EMCURE vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emcure Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Emcure Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 13.82% mean?
Emcure Pharmaceuticals (NSE:EMCURE) has a Return-on-Tangible-Asset of 13.82% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Emcure Pharmaceuticals and its competitors. This is 50% above median its historical median of 9.23. Over the past decade, Emcure Pharmaceuticals' Return-on-Tangible-Asset has ranged from 6.51 to 12.55. According to the industry distribution chart, Emcure Pharmaceuticals ranks #180 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 17.9%.
Is Emcure Pharmaceuticals' Return-on-Tangible-Asset too high?
Emcure Pharmaceuticals' current Return-on-Tangible-Asset of 13.82% is 50% above median its 10-year median of 9.23. Over the past 10 years, this metric has ranged from a low of 6.51 to a high of 12.55. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.99. Emcure Pharmaceuticals' value of 13.82% is 362.2% above this industry median. Based on the distribution chart, Emcure Pharmaceuticals ranks #180 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emcure Pharmaceuticals ranks #180 out of 1007 companies for Return-on-Tangible-Asset. This places Emcure Pharmaceuticals in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.99. Emcure Pharmaceuticals' value of 13.82% is 362.2% above this benchmark. Historically, Emcure Pharmaceuticals' own Return-on-Tangible-Asset has ranged from 6.51 to 12.55 over the past decade. While the company's 10-year median is 9.23 vs. the industry median of 2.99, Emcure Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.99, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emcure Pharmaceuticals's current Return-on-Tangible-Asset of 13.82% is 362.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Emcure Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emcure Pharmaceuticals's current Return-on-Tangible-Asset is 13.82%, which is 50% above median its own 10-year median of 9.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current Return-on-Tangible-Asset of 13.82%. The current Return-on-Tangible-Asset is 13.82%, which is 50% above median its 10-year median of 9.23 and 362.2% above the Drug Manufacturers industry median of 2.99. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current Return-on-Tangible-Asset is 13.82% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score
Get the complete analysis for NSE:EMCURE
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:EMCURE has been successfully added to your 
